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 EDiTOr’S cAOrNEr SpEciAL fOcuS LETTEr frOm ThE guEST EDiTOr: TArgETiNg JAK-STAT iN DiSEASES
So-called oncogenic transcription factors are not themselves 
mutated in cancer, but mediate the effects of a diverse array of 
activated kinases in regulating the genes that control prolif-
eration, survival, invasion and spread that underlie malignancy. 
Reflecting their role in the physiological control of these pro-
cesses, STAT family members, particularly STAT3 and STAT5, 
were found to be activated inappropriately in a wide range of 
human cancers. Inhibition of these proteins in cancer models 
shows significant therapeutic benefit; by contrast, loss of func-
tion in normal cells is well tolerated, likely due to redundancies 
in physiological signal transduction. Thus, STATs appear to be 
targets with the potential for a high therapeutic index. However, 
while great progress has been made in developing inhibitors to 
a range of kinases, the ability to target transcription factors has 
lagged far behind. In fact, for a variety of reasons transcription 
factors in general, and STATs in particular, were termed “undrug-
gable.” Kinases have well-defined pockets into which ATP binds, 
and into which a small organic molecule can be designed to fit. 
By contrast, transcription factors interact with other proteins and 
with DNA through interfaces with large surface area, suggesting 
that it would be extremely difficult to design a molecule with 
drug-like properties that could inhibit their function.
As increasing numbers of experimental studies provide ever-
stronger support for targeting oncogenic transcription factors 
like STATs, novel approaches for inhibiting these proteins have 
emerged. In this issue of JAK-STAT, four papers present a range 
of creative and complementary strategies to targeting STATs, 
particularly STAT3. Although STATs lack conventional enzyme 
activity, they do contain clearly defined domains necessary for 
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their function. One such motif is the SH2 domain, which allows 
tyrosine phosphorylated STATs to form transcriptionally active 
dimers. McMurray et al. discuss the efforts from their lab and 
others to design small molecules to specifically block this interac-
tion.1 The fact that the phosphopeptide sequence from STAT3 
can bind to this region provides a starting point in designing such 
inhibitors. Clever synthetic chemistry strategies can then be used 
to generate phosphopeptide mimetics with therapeutic activity.
As a basic understanding of the nature of STAT transcrip-
tional regulation emerged, it became clear that STATs not only 
function as dimers, but they can form tetramers as well, through 
an N-terminal domain. This may allow STATs to bind tandem 
sites with lower intrinsic affinity, permit non-tyrosine phosphory-
lated STATs to have transcriptional activity, and provide STATs 
with a more nuanced regulation of gene expression based on 
the magnitude of the stimulus and other biological parameters. 
Using a lipopeptide strategy, Timofeeva and Tarasova describe 
the development of N-terminal domain inhibitors that hold great 
therapeutic promise.2
The paper by Sen and Grandis highlights several novel aspects 
of targeting STATs.3 First, the term “undruggable” refers to the 
difficulty of developing small organic molecules. These authors 
point out that macromolecules, particularly nucleic acids, hold 
great promise as therapeutic agents, with a considerable track 
record of safety in humans. Further, they note that another 
domain of STATs, the DNA binding domain, is an appealing 
target. Decoy oligonucleotides can allow activated STATs to be 
diverted from their genomic targets, and block STAT-dependent 
gene expression. Furthermore, to their enormous credit, the 
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Grandis team truly achieved clinical translation of their strategy. 
They conducted a phase 0 clinical trial using decoy oligonucle-
otides in patients with squamous cell carcinoma of the head and 
neck, and demonstrated evidence of inhibition of STAT3 target 
genes in the tumor. This is a landmark study, and definitively 
refutes the notion that transcription factors cannot be targeted 
therapeutically.
Finally, the manuscript by Walker and Frank takes a different 
tack to identifying STAT inhibitors.4 Rather than using target-
based design strategies, these authors discuss the development of 
cell-based transcription-dependent systems that can be used to 
screen chemical libraries for STAT modulators. Active molecules 
arising from these screens may be targeting STATs directly, or 
may be affecting critical cellular regulators of the STAT pathway. 
Hits from these screens can thus provide insight into the cellu-
lar signaling network, and may reveal critical targets that might 
otherwise be unappreciated. This group has used this strategy 
to identify a small molecule inhibitor of STAT3 transcriptional 
activity that is now in a clinical trial in patients with chronic 
lymphocytic leukemia (CLL).
Of course, this is not the end of the development of STAT 
inhibitors for the therapy of cancer and other diseases, but rather 
just the beginning. Many key biological questions remain such 
as, what is the role of non-transcriptional functions of STATs 
particularly in the mitochondria or cytoskeleton, what is the rela-
tion between inhibition of STATs and activation of other path-
ways, and why does inhibition of STAT tyrosine phosphorylation 
correlate with some therapeutic responses but not others? There 
are also important unanswered therapeutic questions such as 
whether the combination of STAT inhibitors that work through 
different mechanisms may synergize when combined, or what are 
optimal therapeutic combinations of STAT inhibitors with other 
therapeutic modalities? Given that STAT inhibitors have now 
been brought to the clinic, it is likely that interest in the topics 
reviewed in these articles will only increase from basic, trans-
lational, and clinical investigators. In any case, with regard to 
targeting STATs therapeutically, it seems safe to retire the word 
“undruggable.”
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